Clincosm LogoSign in Get a demo

EuroCOV: Risk Stratification of Patients With Suspected COVID-19 Presenting to the ED

Sponsor
University Hospital, Tours (Other)
Overall Status
Completed
CT.gov ID
NCT05465824
Collaborator
(none)
7,876
Enrollment
1
Location
2.8
Actual Duration (Months)
2853.9
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Descriptive study of patients with suspected COVID-19 upon ED arrival of European hospitals between March 09 and April 08 2020.

Justification:

Over the past 3 months, the world has faced a novel infection disease outbreak, due to a novel coronavirus, the severe acute respiratory syndrome coronavirus (SARS-CoV2), with a massive impact on healthcare resource.

In Europe, numbers of confirmed cases continue to rise. Europe is currently one of the regions with the highest number of Covid-19 cases and deaths due to this emergent diseases.

Most COVID-19 infected patients present with mild to moderate acute respiratory symptoms, including cough, fever, dyspnea and pneumonia. About 20% will present with severe or critical manifestations of the disease, including pneumonia, respiratory failure and acute respiratory distress syndrome (ARDS).

Anticipating the needs for hospitalization in ward and/or intensive care is crucial.

Emergency departments are at the front line for triaging patients with suspected Covid-19 and referring them to the appropriate level of care.

In Europe, the number of ED patients with suspected Covid-19 is variable; rate of hospitalization from ED reaches 40% for this population.

Risk stratification and management decisions of patients presenting to the ED with suspected COVID-19 is a challenge for emergency physicians.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    7876 participants
    Observational Model:
    Other
    Time Perspective:
    Retrospective
    Official Title:
    Risk Stratification of Patients With Suspected COVID-19 Presenting to the ED
    Actual Study Start Date :
    Mar 9, 2020
    Actual Primary Completion Date :
    Apr 8, 2020
    Actual Study Completion Date :
    Jun 1, 2020

    Outcome Measures

    Primary Outcome Measures

    1. Mortality [through study completion, an average of 30 days]

      Mortality during hospital management

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    Adult patients (>= 18 years old) attending the ED with a clinical suspicion of COVID-19 based on the presence of the following criteria

    • Fever >= 38 °C

    • respiratory symptoms (dyspnea, cough, expectorations)

    • any other symptoms suggestive of COVID-19 including digestive signs (diarrhea, anosmia…)

    Exclusion Criteria:

    • No insurance

    • patients less than 18 years

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Tours University Hospital Tours France 37044

    Sponsors and Collaborators

    • University Hospital, Tours

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Saïd LARIBI, Principal Investigator, University Hospital, Tours
    ClinicalTrials.gov Identifier:
    NCT05465824
    Other Study ID Numbers:
    • EuroCOV
    First Posted:
    Jul 20, 2022
    Last Update Posted:
    Jul 20, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    COVID-19

    Study Results

    No Results Posted as of Jul 20, 2022